US61023L2079
US61023L2079
Monopar Therapeutics Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 529.99M EUR | 621.48M EUR | 367.04M EUR | 437M EUR |
Enterprise Value | 429.59M EUR | 568.83M EUR | 314.63M EUR | 375.32M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -41.22x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 4.05x | 4.75x | 2.71x | 3.17x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -- | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.15% | -1.96% | -2.73% | -1.5% |